To study the biodistribution of anti-CSPG-IgE, a previously described mouse model of melanoma with a humanized immune system was employed.49 A detailed study of the anti-tumor efficacy of the anti-CSPG4 IgE was recently performed by Chauhan et al., showing that this antibody significantly delayed the growth of A375 tumors, resulted in increased macrophage recruitment to tumor tissue and prolonged survival of mice bearing patient-derived melanoma xenografts.34 This evidence concerns the gene CSPG4 and neoplasm.